Cyclin D1 expression in prostate carcinoma

Brazilian Journal of Medical and Biological Research

Volumn 47, Issue 6, 2014, Pages 515-521

  Pereira, R A ^a   Ravinal, R C ^a   Costa, R S ^a   Lima, M S ^a   Tucci, S ^a   Muglia, V F ^a   Dos Reis, R B ^a   Silva, G E B ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cyclin D1; Immunohistochemistry; Prostate cancer

Indexed keywords

CYCLIN D1; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; DISEASE ASSOCIATION; FEMALE; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PERINEURAL INVASION; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; BLOOD; CANCER GRADING; CARCINOMA; GENETICS; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; STAINING; STATISTICS;

AGED; CARCINOMA; CYCLIN D1; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; STAINING AND LABELING; STATISTICS AS TOPIC;

EID: 84901657477     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20143240     Document Type: Article

References (29)

1. Dunn MW, Kazer MW. Prostate cancer overview. Semin Oncol Nurs 2011; 27: 241-250, doi: 10.1016/j.soncn.2011.07. 002.
2. INCA. Estimativa 2014. In: Ministério da Saú de (Editor), Incidência de câncer no Brasil. Rio de Janeiro: INCA; 2014. http://www.inca.gov.br/estimativa/2014/estimativa-24012014. pdf.
3. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993; 7: 812-821, doi: 10.1101/gad.7.5.812.
4. Diehl JA. Cycling to cancer with cyclin D1. Cancer Biol Ther 2002; 1: 226-231.
5. Donnellan R, Chetty R. Cyclin D1 and human neoplasia. Mol Pathol 1998; 51: 1-7, doi: 10.1136/mp.51.1.1.
6. Drobnjak M, Osman I, Scher HI, Fazzari M, Cordon-Cardo C. Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. Clin Cancer Res 2000; 6: 1891-1895.
7. Fleischmann A, Rocha C, Saxer-Sekulic N, Zlobec I, Sauter G, Thalmann GN. High-level cytoplasmic cyclin D1 expression in lymph node metastases from prostate cancer independently predicts early biochemical failure and death in surgically treated patients. Histopathology 2011; 58: 781-789, doi: 10.1111/j.1365-2559.2011.03800.x.
8. Kolar Z, Murray PG, Scott K, Harrison A, Vojtesek B, Dusek J. Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer. Mol Pathol 2000; 53: 15-18, doi: 10.1136/mp.53.1.15.
9. Aaltomaa S, Karja V, Lipponen P, Isotalo T, Kankkunen JP, Talja M, et al. Expression of Ki-67, cyclin D1 and apoptosis markers correlated with survival in prostate cancer patients treated by radical prostatectomy. Anticancer Res 2006; 26: 4873-4878.
10. Nakamura Y, Felizola SJ, Kurotaki Y, Fujishima F, McNamara KM, Suzuki T, et al. Cyclin D1 (CCND1) expression is involved in estrogen receptor beta (ERbeta) in human prostate cancer. Prostate 2013; 73: 590-595, doi: 10.1002/pros.22599.
11. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-439, doi: 10.1001/ jama.294.4.433.
12. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095-1101, doi: 10.1016/j.urology.2007.03.042.
13. Nardi AC, Reis RB, Zequi Sde C, Nardozza A Jr. Comparison of the epidemiologic features and patterns of initial care for prostate cancer between public and private institutions: a survey by the Brazilian Society of Urology. Int Braz J Urol 2012; 38: 155-164, doi: 10.1590/S1677-55382 012000200003.
14. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level, or =4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246, doi: 10.1056/ NEJMoa031918.
15. Kallakury BV, Sheehan CE, Ambros RA, Fisher HA, Kaufman RP Jr, Ross JS. The prognostic significance of p34cdc2 and cyclin D1 protein expression in prostate adenocarcinoma. Cancer 1997; 80: 753-763, doi: 10.1002/ (SICI)1097-0142(19970815)80:4,753::AID-CNCR15.3.0. CO;2-S.
16. Comstock CE, Revelo MP, Buncher CR, Knudsen KE. Impact of differential cyclin D1 expression and localisation in prostate cancer. Br J Cancer 2007; 96: 970-979, doi: 10.1038/sj.bjc.6603615.
17. Ilia Anis HNH, Darweesh MF, Abd El Rahman M. Immunohistochemical expression of Cyclin D1 in Egyptian patients with prostatic carcinoma. World J Med Sci 2013; 8: 306-313.
18. Han EK, Lim JT, Arber N, Rubin MA, Xing WQ, Weinstein IB. Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors. Prostate 1998; 35: 95-101, doi: 10.1002/(SICI)1097-0045(19980501)35:2,95::AIDPROS2.3.0. CO;2-F.
19. Aquino G, Franco R, Ronconi F, Anniciello A, Russo L, De Chiara A, et al. Peripheral T-cell Lymphoma with Cyclin D1 overexpression: a case report. Diagn Pathol 2012; 7: 79, doi: 10.1186/1746-1596-7-79.
20. Gillett C, Smith P, Gregory W, Richards M, Millis R, Peters G, et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996; 69: 92-99, doi: 10.1002/(SICI)1097-0215(19960422)69:2,92::AID-IJC4.3.0.CO;2-Q.
21. Emin Özbek BM, Mustafa Özbek, Süleyman Büyükberber MD. Cyclin-D1 protooncogen expression in prostate cancer. Turkish J Cancer 2000; 30.
22. Ding GX, Liu J, Feng CC, Jiang HW, Xu JF, Ding Q. Slug regulates Cyclin D1 expressionin by ubiquitin-proteasome pathway in prostate cancer cells. Panminerva Med 2012; 54: 219-223.
23. He Y, FrancoOE, JiangM, Williams K, Love HD, Coleman IM, et al. Tissue-specific consequences of cyclin D1 overexpression in prostate cancer progression. Cancer Res 2007; 67: 8188-8197, doi: 10.1158/0008-5472.CAN-07-0418.
24. Koontz BF, Tsivian M, Mouraviev V, Sun L, Vujaskovic Z, Moul J, et al. Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers. Int J Radiat Oncol Biol Phys 2012; 82: 200-203, doi: 10.1016/ j.ijrobp.2010.11.023.
25. Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, et al. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. BJU Int 2013; 111: 723-730, doi: 10.1111/j.1464-410X.2012.11114.x.
26. Becker C, Noldus J, Diamandis E, Lilja H. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit Rev Clin Lab Sci 2001; 38: 357-399, doi: 10.1080/20014091084236.
27. Brawer MK, Crawford ED, Fowler J, Lucia MS, Schroeder FH. Prostate cancer: epidemiology and screening. Rev Urol 2000; 2 (Suppl 4): S5-S9.
28. Cookson MS, Fleshner NE, Soloway SM, Fair WR. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol 1997; 157: 559-562, doi: 10.1016/ S0022-5347(01)65201-7.
29. Kulkarni JN, Valsangkar RS, Jadhav YR, Singh DP. Impact of Gleason pattern up gradation after radical prostatectomy for carcinoma prostate patients with low biopsy score (#6). J Cancer Res Ther 2011; 7: 459-462, doi: 10.4103/0973-1482.92021.